全文获取类型
收费全文 | 1857篇 |
免费 | 248篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 78篇 |
妇产科学 | 49篇 |
基础医学 | 206篇 |
口腔科学 | 17篇 |
临床医学 | 190篇 |
内科学 | 438篇 |
皮肤病学 | 27篇 |
神经病学 | 136篇 |
特种医学 | 186篇 |
外科学 | 175篇 |
综合类 | 71篇 |
一般理论 | 3篇 |
预防医学 | 283篇 |
眼科学 | 21篇 |
药学 | 144篇 |
中国医学 | 6篇 |
肿瘤学 | 77篇 |
出版年
2023年 | 10篇 |
2021年 | 27篇 |
2020年 | 12篇 |
2019年 | 19篇 |
2018年 | 25篇 |
2017年 | 20篇 |
2016年 | 40篇 |
2015年 | 66篇 |
2014年 | 39篇 |
2013年 | 60篇 |
2012年 | 66篇 |
2011年 | 77篇 |
2010年 | 68篇 |
2009年 | 59篇 |
2008年 | 102篇 |
2007年 | 84篇 |
2006年 | 82篇 |
2005年 | 95篇 |
2004年 | 83篇 |
2003年 | 49篇 |
2002年 | 90篇 |
2001年 | 66篇 |
2000年 | 52篇 |
1999年 | 49篇 |
1998年 | 37篇 |
1997年 | 47篇 |
1996年 | 46篇 |
1995年 | 41篇 |
1994年 | 36篇 |
1993年 | 39篇 |
1992年 | 37篇 |
1991年 | 34篇 |
1990年 | 40篇 |
1989年 | 56篇 |
1988年 | 43篇 |
1987年 | 31篇 |
1986年 | 29篇 |
1985年 | 27篇 |
1984年 | 25篇 |
1983年 | 22篇 |
1982年 | 16篇 |
1981年 | 16篇 |
1980年 | 17篇 |
1979年 | 18篇 |
1978年 | 10篇 |
1976年 | 17篇 |
1974年 | 8篇 |
1971年 | 8篇 |
1970年 | 14篇 |
1968年 | 14篇 |
排序方式: 共有2117条查询结果,搜索用时 247 毫秒
71.
目的分析先天性肠闭锁病例的诊断及治疗,以提高治愈率及术后生活质量。方法回顾性分析166例先天性肠闭锁的临床资料。结果治愈142例,治愈率85.5%(142/166),其中包括18例二期手术治愈者;术中10例、术后8例放弃治疗;术后死亡6例。结论早期诊断和选择合理的术式是提高肠闭锁治愈率的关键,基础支持及手术技术改进能促进病情的恢复,改善预后。 相似文献
72.
73.
74.
Peterson Carla A. Hughes-Belding Kere Rowe Neil Fan Liuran Walter Melissa Dooley Leslie Wang Wen Steffensmeier Chloe 《Maternal and child health journal》2018,22(1):3-12
Objectives This study was conducted to look inside home visits to examine active intervention ingredients used and their relations with ratings of home visit quality. In particular, triadic interactions that engage the home visitor, parent, and child together and provide a context for home visitors to facilitate parent-child interactions by observing, modeling and coaching behaviors that promote optimal child development were examined. Methods Observations were conducted to describe intervention activities (with the HVOF-R) and rate quality of home visit practices and engagement (with the HOVRS A+). Results Analyses revealed the majority of home visit time (71%) was spent in home visitor-parent interactions with only a small proportion of home visit time (17%) spent in triadic interactions and an even smaller proportion of time (2%) during which home visitors actively coached parent-child interactions. Amount of time spent in triadic interactions was related positively to quality ratings of home visit practices and engagement. Moreover, time spent coaching parent-child interactions uniquely predicted home visit quality after accounting for visit length and home visitor time spent observing and modeling. Conclusions for Practice Increasing the percentage of home visitors engage the parent and child in triadic interaction should be a focus for home visiting programs. Home visitors will likely need professional development and supervisory support to enhance their skills in coaching parent-child interactions during triadic interactions. 相似文献
75.
Peterson Carla A. Hughes-Belding Kere Rowe Neil Fan Liuran Walter Melissa Dooley Leslie Wang Wen Steffensmeier Chloe 《Maternal and child health journal》2018,22(1):115-115
Maternal and Child Health Journal - The article “Triadic interactions in MIECHV: Relations to home visit quality”, written by Carla A. Peterson, Kere Hughes-Belding, Neil Rowe, Liuran... 相似文献
76.
77.
Analogues of oxytocin and deaminooxytocin with 4-glutamine replaced by 4-glutamic acid methyl ester readily lose their uterotonic activity when incubated with rat serum, presumably by hydrolysis to the much less active 4-glutamic acid derivatives. On the other hand, inactivation of the deaminooxytocin analogue in the rat uterus, as demonstrated by the 'oil-bath'technique, is only slightly more rapid than that of deaminooxytocin and distinctly slower than that of oxytocin. Its in situ/in vitro ratio of uterotonic activity is less than 0.1 whereas that for deaminooxytocin is about 3 and also the persistence of the uterotonic effect in situ is slightly less than that of deaminooxytocin. The results with these 'rapidly inactivated'analogues can be used as proof of some predictions of the three-compartment model for tissue distribution of neurohypophysial hormones and its influence upon the time course of a biological response published earlier. The potential use of analogues of neurohypophysial hormones as probes for inactivation mechanisms and the results thus far obtained are discussed. 相似文献
78.
Two patients with hairy cell leukemia with massive splenomegaly and severe pancytopenia were treated with recombinant alpha-A interferon (IFN-alpha-2a). There was no significant response to a trial of IFN- alpha-2a (11 and 20 weeks) with respect to blood counts or spleen size. Subsequent treatment with 2'-deoxycoformycin (dCF) for 8 consecutive weeks (4 mg/m2/wk) resulted in normalization of spleen size and a normalization of peripheral blood counts and bone marrow in one patient. The second patient demonstrated a reduction in spleen size and improved blood counts following 9 weeks of dCF therapy but eventually became refractory. This demonstrates that dCF is non-cross-resistant with interferon and confirms the efficacy of dCF in nonsplenectomized patients. 相似文献
79.
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial 总被引:7,自引:0,他引:7
下载免费PDF全文
![点击此处可从《Annals of the rheumatic diseases》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Antoni C Krueger GG de Vlam K Birbara C Beutler A Guzzo C Zhou B Dooley LT Kavanaugh A;IMPACT Trial Investigators 《Annals of the rheumatic diseases》2005,64(8):1150-1157
OBJECTIVES: To evaluate further in a phase III, double blind trial the efficacy of infliximab in patients with active psoriatic arthritis (PsA), as observed in the smaller IMPACT trial. METHODS: 200 patients with active PsA unresponsive to previous treatment were randomised to infusions of infliximab 5 mg/kg or placebo at weeks 0, 2, 6, 14, and 22. Patients with inadequate response entered early escape at week 16. The primary measure of clinical response was ACR20. Other measures included Psoriatic Arthritis Response Criteria (PsARC), Psoriasis Area and Severity Index (PASI), and dactylitis and enthesopathy assessments. RESULTS: At week 14, 58% of patients receiving infliximab and 11% of those receiving placebo achieved an ACR20 response and 77% of infliximab patients and 27% of placebo patients achieved PsARC (both p<0.001). Among the 85% of patients with at least 3% body surface area psoriasis involvement at baseline, 53/83 (64%) patients receiving infliximab had at least 75% improvement in PASI compared with 2/87 (2%) patients receiving placebo at week 14 (p<0.001). These therapeutic effects were maintained through the last evaluation (week 24). Fewer infliximab patients than placebo patients had dactylitis at week 14 (18% v 30%; p = 0.025) and week 24 (12% v 34%; p<0.001). Fewer infliximab patients (22%) than placebo patients (34%) had active enthesopathy at week 14 (p = 0.016); corresponding figures at week 24 were 20% and 37% (p = 0.002). Infliximab was generally well tolerated, with a similar incidence of adverse events in each group. CONCLUSIONS: Infliximab 5 mg/kg through 24 weeks significantly improved active PsA, including dactylitis and enthesopathy, and associated psoriasis. 相似文献
80.
Auber ML; Horwitz LJ; Blaauw A; Khorana S; Tucker S; Woods T; Warmuth M; Dicke KA; McCredie KB; Spitzer G 《Blood》1988,71(1):166-172
Relatively nonmyelotoxic drugs and drug combinations were investigated for their ability to eliminate malignant cells from human bone marrow. In vitro 90% inhibitory concentration (IC90) doses were established on granulocyte macrophage colony-forming units (GM-CFU) in culture of bone marrow by using the GM-CFU assay for the following drugs: 4- hydroperoxycyclophosphamide (4-HC), Adriamycin, L-asparaginase, bleomycin, hydrocortisone, VP-16, spirogermanium, Taxol, and vincristine. The leukemic cell kill efficiency of these drugs at IC90 doses was compared with that of 4-HC on acute lymphoid leukemia (ALL) cell lines by using the limiting-dilution assay. Under these conditions, no single drug was superior to 4-HC. To increase the in vitro effect in leukemic cell kill, combinations of vincristine with hydrocortisone, Adriamycin, VP-16, and 4-HC were investigated. Vincristine at 1 to 5 micrograms/mL increased the marrow cytotoxicity of hydrocortisone, Adriamycin, and VP-16, but it was protective (subadditive) with 4-HC. Vincristine and 4-HC in combination was additive to supraadditive on ALL cell lines, increased the leukemic cell kill by one to two logs above 4-HC alone at IC90 doses (P less than .05), and was not affected by the addition of excess marrow cells. The recommended doses for chemopurging in clinical studies are vincristine, 1 to 5 micrograms/mL, plus 4-HC, 5 micrograms/mL. 相似文献